Buspirone Does Not Cause Anorexia (Loss of Appetite)
Buspirone is not associated with causing anorexia or loss of appetite as a side effect. In fact, the evidence suggests buspirone may be beneficial for treating early satiety and fullness symptoms in certain gastrointestinal conditions, though it is not a first-line treatment.
Understanding the Evidence
FDA Drug Label Information
The FDA-approved prescribing information for Buspar (buspirone) does not list anorexia or loss of appetite as a recognized adverse effect 11. The most common side effects documented are:
- Dizziness and headache
- Nervousness and lightheadedness
- Nausea (gastrointestinal upset, not appetite suppression)
In overdose situations (up to 375 mg/day in clinical trials), symptoms included nausea, vomiting, dizziness, and gastric distress—but not anorexia 1.
Clinical Guideline Context
The 2025 AGA gastroparesis guidelines actually position buspirone as a potential treatment option for patients with predominant early satiety and fullness, suggesting it may help with appetite-related symptoms rather than cause them 22. However, the guideline recommends against buspirone as first-line treatment (conditional recommendation, very low evidence quality), noting it may benefit patients who value potential improvement in early satiety, postprandial fullness, and bloating.
Research Evidence
A 2023 randomized controlled trial specifically examined buspirone for early satiety in gastroparesis patients 3. While the primary outcome showed no significant benefit overall, this study was designed to treat early satiety—not because buspirone causes it. Additionally, research in animal models showed buspirone actually enhanced feeding duration in novel environments, though this was context-dependent 4.
Interestingly, one study in spontaneously hypertensive rats found buspirone induced weight loss through metabolic mechanisms (PPARδ pathway activation), but this was related to increased energy expenditure and fat metabolism—not appetite suppression 5.
What You Should Do
If a Patient Reports Appetite Loss on Buspirone:
Investigate alternative causes first:
- Review all concurrent medications (many psychotropics can cause anorexia)
- Assess for underlying psychiatric conditions (depression, anxiety disorders themselves cause appetite changes)
- Evaluate for gastrointestinal pathology
- Consider drug interactions—buspirone is metabolized by CYP3A4, and interactions with inhibitors can increase buspirone levels and side effects 11
Verify the temporal relationship:
- Did appetite loss truly begin after buspirone initiation?
- Has the dose been recently increased?
- Are there CYP3A4 inhibitors present (erythromycin, itraconazole, grapefruit juice, diltiazem, verapamil)?
If buspirone is genuinely suspected:
- This would be an atypical reaction not supported by the drug label
- Consider dose reduction or switching to an alternative anxiolytic
- Document this as an idiosyncratic reaction
Important Caveats:
The context matters significantly. If you're asking about buspirone use in a patient with an eating disorder (anorexia nervosa), this is a completely different clinical scenario. The 2023 APA eating disorder guidelines do not recommend buspirone for treating anorexia nervosa 666. The guidelines emphasize eating disorder-focused psychotherapy and family-based treatment for anorexia nervosa, with no role for buspirone in the treatment algorithm.
Buspirone is contraindicated in patients with bulimia or anorexia nervosa when combined with bupropion/naltrexone 7, but this is due to bupropion's contraindication in eating disorders, not buspirone itself.
Bottom line: Buspirone does not cause anorexia as a recognized side effect. If a patient develops appetite loss while taking buspirone, look for other explanations including drug interactions, concurrent medications, or underlying medical/psychiatric conditions.